gimli

KPL stock AI analysis

KPL Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers

KWALITY PHARMACEUTICALS L is a small-cap stock in Healthcare. This Gimli page shows the latest available KPL price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.

Analyze with AI Open interactive KPL stock page

Price

₹3,630.90

1W return

+0.88%

1M return

+1.87%

3M return

+41.72%

6M return

+129.87%

1Y return

n/a

Market cap

₹n/a

n/a

ROE

+27.37%

ROCE

+28.08%

RSI

54.12

Turnover

₹6.47 cr

Why it can matter in screens

Momentum: KPL is above 50DMA, below 200DMA; RSI is 54.12.
Returns: 1D +3.27%, 1W +0.88%, 1M +1.87%, 3M +41.72%, 1Y n/a.
Trend levels: 52W high ₹3,949.00, 52W low ₹2,180.00, off high -8.06%.
Liquidity: latest turnover is ₹6.47 cr; volume vs 20D is +0.63%.
Valuation/profitability: PE n/a, PB n/a, ROE +27.37%, ROCE +28.08%.
Growth: 3Y sales CAGR +25.59%, 3Y profit CAGR +51.22%.

Quick Answers

What is the latest KPL stock price?

The latest stored price for KPL is Rs 3,630.90 as of 2026-11-03.

Is KPL above its 50DMA and 200DMA?

KPL is above 50DMA, below 200DMA. The latest 50DMA is 3,514.56 and the latest 200DMA is n/a.

What are KPL PE, ROE and ROCE?

KPL has PE n/a, ROE +27.37%, and ROCE +28.08% in Gimli's latest available snapshot.

How has KPL performed recently?

KPL has returned +1.87% over 1 month, +41.72% over 3 months, and n/a over 12 months in the latest stored data.

Is this stock page investment advice?

No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.

Financials and Ownership

Quarterly income statement

Period	Revenue	EBITDA	PAT	EPS
2026-06-30	162.97 cr	41.64 cr	25.63 cr	24.69
2026-03-31	158.17 cr	39.82 cr	25.31 cr	24.39
2025-12-31	123.97 cr	30.48 cr	16.00 cr	15.42
2025-09-30	111.95 cr	26.25 cr	14.12 cr	13.60
2025-06-30	111.86 cr	24.55 cr	11.92 cr	11.49
2025-03-31	115.68 cr	26.65 cr	14.49 cr	n/a

Annual income statement

Year	Revenue	EBITDA	PAT	EPS
2026-03-31	503.06 cr	120.27 cr	67.35 cr	n/a
2025-03-31	372.12 cr	82.36 cr	39.89 cr	38.44
2024-03-31	309.00 cr	61.36 cr	23.98 cr	23.11
2023-03-31	253.94 cr	46.70 cr	19.47 cr	18.45
2022-03-31	459.64 cr	175.24 cr	120.05 cr	115.36

Balance sheet

Period	Assets	Cash	Debt	Equity
2026-03-31	592.21 cr	0.74 cr	130.70 cr	329.92 cr
2025-03-31	447.27 cr	12.02 cr	112.45 cr	262.40 cr
2024-03-31	394.21 cr	2.26 cr	98.12 cr	222.58 cr
2023-03-31	353.63 cr	3.07 cr	90.26 cr	199.07 cr

Cash flow

Period	OCF	FCF	Cash change
2026-03-31	16.59 cr	-32.35 cr	n/a
2025-03-31	52.72 cr	27.72 cr	n/a
2024-03-31	42.98 cr	13.14 cr	n/a
2023-03-31	41.38 cr	-6.29 cr	n/a
2022-03-31	n/a	n/a	n/a

Shareholding Trend

No recent data available.

Industry Peers

Symbol	Name	Mcap	PE	ROE	1Y
SUNPHARMA	SUN PHARMACEUTICAL IND L	424,658.30 cr	35.053345	+15.50%	+3.72%
DIVISLAB	DIVI S LABORATORIES LTD	267,167.60 cr	91.684145	+18.37%	+47.91%
TORNTPHARM	TORRENT PHARMACEUTICALS L	157,377.11 cr	74.094685	+16.87%	+28.16%
LAURUSLABS	LAURUS LABS LIMITED	125,408.69 cr	114.827348	+21.77%	+138.16%
ZYDUSLIFE	ZYDUS LIFESCIENCES LTD	124,833.39 cr	27.818646	+16.04%	+26.46%
APOLLOHOSP	APOLLO HOSPITALS ENTER. L	121,354.29 cr	57.614911	+22.62%	+7.87%
DRREDDY	DR. REDDY S LABORATORIES	113,923.95 cr	40.698752	+7.80%	+14.41%
CIPLA	CIPLA LTD	112,841.65 cr	38.950805	+8.80%	-7.58%

Try these prompts

Analyze KWALITY PHARMACEUTICALS L with valuation, momentum and industry peers
Compare KPL with other Healthcare stocks
Show small-cap stocks in Healthcare above 50DMA with positive 1M return
Find Healthcare stocks with improving momentum and reasonable valuation

Related screen ideas

Data snapshot: 2026-11-03. Not investment advice.